<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192487</url>
  </required_header>
  <id_info>
    <org_study_id>NP 303-103</org_study_id>
    <nct_id>NCT04192487</nct_id>
  </id_info>
  <brief_title>Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea</brief_title>
  <official_title>A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Napo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Napo Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate:&#xD;
&#xD;
        1. Any changes in the gut microbiome from baseline compared to end of study in both healthy&#xD;
           (HIV-negative) subjects and HIV+ patients with or without chronic diarrhea, following&#xD;
           one month of treatment with crofelemer (Mytesi), delayed release 125 mg tablets twice&#xD;
           daily (BID) following one month of treatment.&#xD;
&#xD;
        2. The safety and tolerability of crofelemer, (Mytesi) delayed release 125 mg tablets BID&#xD;
           in healthy (HIV-negative) volunteers and HIV+ patients following one month of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mytesi ®(crofelemer) is an FDA-approved anti-diarrheal drug indicated for the symptomatic&#xD;
      relief of non-infectious diarrhea in adult patients with HIV/AIDS on combination&#xD;
      anti-retroviral therapy (CART). Crofelemer, a first-in-class intraluminally active,&#xD;
      use-dependent chloride (Cl-) ion channel modulator that produces an antidiarrheal effect by&#xD;
      reducing Cl- secretion and the accompanying high-volume fluid secretion into the GI lumen.&#xD;
&#xD;
      This Phase 4 trial will explore the induced gut microbiome changes in comparison to a group&#xD;
      of normal healthy volunteers also receiving crofelemer delayed release 125 mg tablets twice&#xD;
      daily for 30 days.&#xD;
&#xD;
      This is a non-randomized study. The study will enroll approximately 24 male or female&#xD;
      subjects aged at least 18 years in three cohorts of approximately 8 subjects each.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in gut microbiome</measure>
    <time_frame>Screening (Visit 1/Day -21) to end of Study Visit 4 (Day 60)</time_frame>
    <description>Stool microbiomes will be evaluated to compare the differences in the stool microbiome at Visits 2, (Day 1) Visit 3 (Day 30) and Visit 4 (Day 60) using a proprietary microbiome statistical tool (μScope) and R statistical computing and graphics software.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reduction in the number of watery BMs</measure>
    <time_frame>From baseline (Day -7) to end of study (Day 60)</time_frame>
    <description>Defined as a score of 6 or 7 on the Bristol Stool Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in Daily GI symptom Scale (DGIS)</measure>
    <time_frame>From baseline (Day -7) to end of study (Day 60)</time_frame>
    <description>Daily presence or absence of abdominal pain, bloating, gurgling, flatulence, and bowel incontinence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Healthy Volunteers</condition>
  <condition>HIV/AIDS</condition>
  <condition>HIV Diarrhea</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers (HIV-negative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+ Patients (Fully Suppressed, Viral Load &lt; 50c/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+ Patients (Not fully suppressed viral load &gt; 1000c/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crofelemer delayed-release tablets 125mg</intervention_name>
    <description>1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.</description>
    <arm_group_label>HIV+ Patients (Fully Suppressed, Viral Load &lt; 50c/mL)</arm_group_label>
    <arm_group_label>HIV+ Patients (Not fully suppressed viral load &gt; 1000c/mL</arm_group_label>
    <arm_group_label>Healthy Volunteers (HIV-negative)</arm_group_label>
    <other_name>Mytesi delayed-release tablets 125mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary informed consent from the subject to be obtained in accordance with&#xD;
             requirements of the Institutional Review Board (IRB) before any study-related&#xD;
             activities are performed.&#xD;
&#xD;
          2. Body Mass Index (BMI) between 18 and 32 kg/m2 (both inclusive).&#xD;
&#xD;
          3. Females of child-bearing potential must have a negative serum pregnancy test result at&#xD;
             Screening and a negative urine pregnancy test at Visit 2.&#xD;
&#xD;
             Inclusion Criteria for Healthy, HIV-negative Volunteers&#xD;
&#xD;
          4. No history or evidence of clinically relevant medical disorders as determined by the&#xD;
             investigator.&#xD;
&#xD;
          5. No history of chronic diarrhea or loose stools and/or non-specific incidence of acute&#xD;
             diarrhea or loose stools between the Screening Visit and Baseline Visit 2 (Day 1).&#xD;
&#xD;
             Inclusion Criteria applicable to all PLWHA subjects&#xD;
&#xD;
          6. Male and female patients receiving a stable CART for ≥ 4 weeks for HIV treatment.&#xD;
&#xD;
          7. Have a history of diarrhea (persistently loose stools despite periodic or regular use&#xD;
             of antimotility medications) or ≥1 watery bowel movement per day (without periodic or&#xD;
             regular use of antimotility drugs); i.e. - diarrhea for a continuous period of ≥1&#xD;
             month.&#xD;
&#xD;
             Inclusion Criteria for PLWHA males and females receiving CART WITHOUT fully suppressed&#xD;
             HIV RNA counts&#xD;
&#xD;
          8. CD4 counts &gt;200/µL at the Screening Visit.&#xD;
&#xD;
          9. Plasma levels of HIV RNA greater than 1,000 copies/mL at the Screening Visit.&#xD;
&#xD;
             Inclusion Criteria for PLWHA males and females receiving CART WITH fully suppressed&#xD;
             HIV RNA counts&#xD;
&#xD;
         10. CD4 counts &gt;400/µL inclusive at the Screening Visit.&#xD;
&#xD;
         11. Plasma levels of HIV RNA &lt; 50 copies/mL at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Applicable to ALL subjects&#xD;
&#xD;
          1. Any serious systemic disease or infection (other than HIV in PLWHA) that occurred&#xD;
             within four weeks prior to Screening, as determined by the Investigator.&#xD;
&#xD;
          2. Patients with active bacterial or parasitic infections requiring antibiotics or&#xD;
             antiparasitic agents will be excluded. Antibiotic or antiparasitic agents used for&#xD;
             prophylaxis are acceptable until 7 days prior to treatment initiation.&#xD;
&#xD;
          3. Stool cultures that are positive for any pathogenic infection at screening visit.&#xD;
&#xD;
          4. Clinically significant cardiovascular disease will include:&#xD;
&#xD;
               1. History of stroke, transient ischemic attack, or myocardial infarction within 6&#xD;
                  months prior to Screening.&#xD;
&#xD;
               2. History of or currently have New York Heart Association Class III-IV heart&#xD;
                  failure prior to Screening.&#xD;
&#xD;
          5. Female subject who is pregnant or breast-feeding or intends to become pregnant or is&#xD;
             of childbearing potential and not using adequate contraceptive methods.&#xD;
&#xD;
          6. Subject has participated in another clinical study, involving an Investigational&#xD;
             Product or an Investigational Device use in the past 1 month prior to commencement of&#xD;
             this study.&#xD;
&#xD;
          7. Use of Mytesi (crofelemer) within 4 weeks of the Screening Visit Applicable to ALL&#xD;
             HIV-negative subjects&#xD;
&#xD;
          8. Positive for Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis B core antibody or hepatitis C antibodies (HepCAb).&#xD;
&#xD;
          9. Presence or history of cancer within the past five years except for adequately treated&#xD;
             localized basal cell skin cancer or in situ uterine cervical cancer.&#xD;
&#xD;
         10. Chronic diarrhea or loose stools requiring antimotility medications including, but not&#xD;
             limited to loperamide, diphenoxylate/atropine, tincture opium and/or octreotide within&#xD;
             2 weeks of the Screening Visit.&#xD;
&#xD;
             Applicable to ALL PLWHA subjects&#xD;
&#xD;
         11. HIV Patients with infectious diarrhea identified by either stool culture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Integrium Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Advocates International</name>
      <address>
        <city>Stratford</city>
        <state>Connecticut</state>
        <zip>06615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, Poles M. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007 May-Jun;41(5):484-90.</citation>
    <PMID>17450031</PMID>
  </reference>
  <reference>
    <citation>Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. Gastroenterology. 2009 May;136(6):1952-65. doi: 10.1053/j.gastro.2008.12.073. Epub 2009 May 7. Review. Erratum in: Gastroenterology. 2009 Jul;137(1):393.</citation>
    <PMID>19457421</PMID>
  </reference>
  <reference>
    <citation>MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012 Sep;55(6):860-7. doi: 10.1093/cid/cis544. Epub 2012 Jun 14. Review.</citation>
    <PMID>22700829</PMID>
  </reference>
  <reference>
    <citation>Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010 Jan;77(1):69-78. doi: 10.1124/mol.109.061051. Epub 2009 Oct 6.</citation>
    <PMID>19808995</PMID>
  </reference>
  <reference>
    <citation>Macarthur RD, Hawkins TN, Brown SJ, Lamarca A, Clay PG, Barrett AC, Bortey E, Paterson C, Golden PL, Forbes WP. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013 Nov-Dec;14(6):261-73. doi: 10.1310/hct1406-261.</citation>
    <PMID>24334179</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination Antiretroviral Therapy (CART)</keyword>
  <keyword>CD4 Cell Count</keyword>
  <keyword>Gut Microbiome</keyword>
  <keyword>Non-Infectious Diarrhea</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

